Novel therapies for renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 10, Issue 6, 2001, Pages 1033-1044

  Fishman, M ^a   Seigne, J ^a   Antonia, S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5 FU; IL 12; Immunotherapy; Razoxane; Renal cell carcinoma; Retinoids; Thalidomide; Von Hippel Lindau protein

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BRYOSTATIN 1; CANCER VACCINE; CAPECITABINE; CYTOKINE; CYTOTOXIC AGENT; EPITOPE; FENRETINIDE; FLAVOPIRIDOL; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; INTERLEUKIN 2; ISOTRETINOIN; RAZOXANE; RECOMBINANT INTERLEUKIN 6; RETINOID; SURAMIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CANCER IMMUNOTHERAPY; CANCER SURGERY; CHROMOSOME ABERRATION; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY CELL; MEDICAL DECISION MAKING; METASTASIS; NEPHRECTOMY; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; STEM CELL TRANSPLANTATION; TUMOR CELL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; HIPPEL-LINDAU DISEASE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 0034988042     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.6.1033     Document Type: Review

References (128)

1. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
2. Initiating genetic events in small renal neoplasms detected by comparative genomic hybridization
3. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation
4. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data
5. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
6. Prediction of metastatic potentials in human renal cell carcinoma by using microarray membrane analysis, genetic and clinical aspects of familiar renal neoplasms
7. Diagnosis and prognosis of renal cell carcinoma: Highlights from an international consensus workshop
8. The Heidelberg classification of renal cell tumours
9. Array-based CGH for the differential diagnosis of renal cell carcinoma
10. Classification of renal cell carcinoma with cdna microarray
11. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma
12. Pattern recognition and arrays: The times are changing
13. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by MRNA differential expression profiling
14. Chemotherapy for renal cell carcinoma
15. Systemic therapy for renal cell carcinoma
16. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
17. Phase II trial of suramin in patients with metastatic renal cell carcinoma
18. A novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II consortium study
19. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
20. A Phase II trial of edatrexate in patients with advanced renal cell carcinoma
21. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a Phase II study
22. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon
23. A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma
24. A phase I-II study of 9-cis retinoic acid and interferonalpha2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study
25. Multicenter Phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma
26. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer
27. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
28. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon alpha-2a
29. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid
30. Continuous low dose thalidomide: A Phase II study in advanced melanoma, renal cell, ovarian and breast cancer
31. Thalidomide treatment of metastatic renal cell carcinoma
32. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interluekin-2 (IL-2) based therapy (Rx)
33. Phase II trial of thalidomide in renal cell carcinoma
34. A Phase II study of razoxane, an antiangiogenic topoisomerase 11 inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis
35. Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma
36. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
37. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
38. Oral Chemotherapy with Capecitabine (xeloda) in the treatment of metastatic renal cancer failing immunotherapy
39. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. The Vienna experience
40. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
41. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
42. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12
43. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity
44. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases
45. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
46. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma
47. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
48. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer
49. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
50. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
51. Phase I trial of subcutaneously administered rHuIL-12 and rHuIFN-a2b in patients with metastatic renal cell carcinoma or malignant melanoma
52. Genetic and clinical aspects of familial renal neoplasms
53. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
54. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
55. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
56. Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
57. Mechanism of regulation of the hypoxiainducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein
58. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
59. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation
60. Accumulation of HIF-1alpha under the influence of nitric oxide
61. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes
62. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells
63. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX
64. Syndrome: Target for anti-vascular endothelial growth factor (VEGF) receptor therapy
65. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
66. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
67. ZD6474: Design, synthesis and structure of a novel, orally active VEGF receptor tyrosine kinase inhibitor
68. Phase I Safety and Pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
69. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma
70. Elevated plasma TGF-1 in renal diseases: Cause of Consequence?
71. Transcriptional control by the TGFbeta/Smad signaling system
72. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans
73. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor
74. Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
75. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
76. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide
77. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
78. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma
79. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido
80. Identification of cancer antigens: Impact on development of cancer immunotherapies
81. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
82. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
83. Metastatic renal cell cancer and radical nephrectom: Identification of prognostic factors and patient survival
84. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
85. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
86. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
87. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma
88. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
89. Cancer vaccines
90. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
91. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA) -A2.1-restricted epitope recognized by cytotoxic T lymphocytes
92. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma
93. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
94. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma
95. Adoptive cellular therapy
96. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
97. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
98. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/1 in interleukin-2 production and immunotherapy
99. Use of dendritic cells to immunize against cancers overexpressing p53
100. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
101. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
102. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
103. Gene-modified dendritic cells for use in tumor vaccines
104. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
105. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
106. Renal cell carcinoma: Natural history and results of treatment
107. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression
108. Nephrectomy in metastatic renal cell carcinoma
109. Renal-cell carcinoma
110. Pulmonary resection of metastatic renal cell carcinoma
111. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma
112. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor
113. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy
114. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study
115. Cytoreduction nephrectomy in metastatic renal cancer
116. Tumor nephrectomy plus alpha Interferon is superior to alpha Interferon alone in metastatic renal cell carcinoma
117. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma
118. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
119. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma
120. Influence of tumor size and surgical resection on cell-mediated immunity in mice
121. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells
122. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma
123. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis
124. Resection of metastatic renal cell carcinoma
125. Resection of pulmonary metastases from renal cell carcinoma
126. Pulmonary resection of metastatic renal cell carcinoma
127. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: An institutional review